A Critical Discourse Analysis of literature in Fairclough’s socio-political Perspective
Data Plus · 2024
DOI: 10.62887/dataplus.002.002.0028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Data Plus, 2024. Verfasst von Gulzar Bibi und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Literature has long been recognized for its profound influence on society, shaping political, social, communal, and personal perspectives. This study examines the transformative power of literature by analyzing its impact through a Critical Discourse Analysis (CDA) framework. Key literary and rhetorical works—including Dr. Martin Luther King Jr.’s speeches I Have a Dream and The Three Evils, Sylvia Plath’s The Bell Jar (1963), and Upton Sinclair’s The Jungle (1905)—are explored to demonstrate how literature challenges societal norms, raises awareness of inequalities and drives social change. By engaging with insights from literary scholars across diverse fields, this research highlights the intersection of discourse, power, and ideology in shaping societal structures. Fairclough’s CDA approach is applied to analyze the socio-political dimensions of these texts, emphasizing their role in exposing and critiquing social, cultural, and political inequalities. Ultimately, this study reinforces the notion that literature—beyond traditional books and poetry—serves as a powerful catalyst for societal transformation.
Zitieren
APA
Bibi, G., & Baig, F. (2024). A Critical Discourse Analysis of literature in Fairclough’s socio-political Perspective. Data Plus. https://doi.org/10.62887/dataplus.002.002.0028
Vancouver
Bibi G, Baig F. A Critical Discourse Analysis of literature in Fairclough’s socio-political Perspective. Data Plus. 2024. doi:10.62887/dataplus.002.002.0028
BibTeX
@article{Bibi2024,
author = {Bibi, Gulzar and Baig, Fatima},
title = {A Critical Discourse Analysis of literature in Fairclough’s socio-political Perspective},
journal = {Data Plus},
year = {2024},
doi = {10.62887/dataplus.002.002.0028}
}
EUVIMED